Is Oramed Pharmaceuticals Inc (ORMP) overvalued? · rev $1.3M
Oramed Pharmaceuticals Inc (ORMP) is a biotechnology company listed on US.
This page asks whether Oramed Pharmaceuticals Inc (ORMP) looks expensive on cached numbers — not a short thesis.
Latest reported ORMP revenue for 2023-12-31 was $1.3M. Net income was $5.5M. Revenue was up 48.2% from 2022-12-31 to 2023-12-31. ORMP currently screens at market cap $87.2M.
ORMP currently screens at market cap $87.2M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ORMP 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ORMP stock page for the full model, not this heading.
Not investment advice.